Moreover, the promotion in NSCLC growth and glycolysis mediated by CAFs‐derived Exos in vivo was reversed by PI3K/AKT pathway inhibitor BKM120, proving the involvement of the PI3K/AKT pathway in this process. Here, AKT1 is linked to non-small cell lung carcinoma.